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Edited by Barry HalliwellAbstract The proteasome mediates pathways associated with
oxidative stress and inﬂammation, two pathogenic events corre-
lated with age-related macular degeneration (AMD). In human
donor eyes corresponding to four stages of AMD, we found the
proteasomal chymotrypsin-like activity increased in neurosen-
sory retina with disease progression. Increased activity corre-
lated with a dramatic increase in the inducible subunits of the
immunoproteasome, which was not due to an increase in CD45
positive immune cells in the retina. The novel observation of pro-
teasome transformation may reﬂect retinal response to local
inﬂammation or oxidative stress with AMD.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The proteasome is a key intracellular protease that regulates
pathways that are critical for cell survival. Diﬀerent oligomeric
forms of the proteasome exist, deﬁned by both the composi-
tion of the catalytic subunits in the 20S core and associated
regulatory complexes [1]. The 20S catalytic core is composed
of four seven-member rings; constitutively expressed a-sub-
units form the outer rings and b-subunits form the inner rings.
The b-subunits contain three pairs of active sites (b1, b2, and
b5) that perform distinct proteolytic activities [2]. The active
sites have been identiﬁed as caspase-like, trypsin-like, and chy-
motrypsin-like for cleavage after acidic, basic, and hydropho-
bic amino acids, respectively.
Following exposure to cytokines, such as interferon c
(IFNc), the constitutive catalytic subunits, b1, b2, and b5
can be replaced in nascent proteasomes by the inducible sub-
units b1i, b2i, and b5i [3]. The exchange of catalytic subunits
to the inducible subunits forms the catalytic core of the immu-
noproteasome. Association of the 20S core containing induc-
ible subunits with the proteasome activator PA28 forms the
immunoproteasome, a specialized form of the proteasome
known to generate immunogenic peptides [4].*Corresponding author. Address: 380 Lions Research Building, 2001
6th Street SE, Minneapolis, MN 55455. Fax: +1 612 626 0781.
E-mail address: ferri013@umn.edu (D.A. Ferrington).
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doi:10.1016/j.febslet.2007.01.061Age-related macular degeneration (AMD) is the leading
cause of vision loss and blindness in individuals over the age
of 65 [5,6]. Considerable evidence implicates retinal oxidative
stress [7] and inﬂammation [8] as critical pathogenic events
with AMD, both of which are partially mediated by the pro-
teasome [9,10]. We have previously utilized the Minnesota
Grading System (MGS) for eyebank eyes [11] to track molec-
ular changes in the neurosensory retina proteome over the
course of the disease [12,13]. We found altered expression of
proteins involved in the proteasomal pathway [12], thus
prompting a more in-depth analysis to investigate how this
essential protein changes with the disease.2. Materials and methods
2.1. Materials
Peptide substrates were purchased from Sigma, Calbiochem, and
BioMol. Proteasome inhibitors were from Peptides International.
Antibodies and their respective companies are as follows: proteasomal
subunits and activators (Aﬃnity Bioreagents and Aﬃniti), HSP90
(Santa Cruz), CD45 and jurkat cell lysate (Epitomics), goat anti-rabbit
or -mouse, donkey anti-goat or -rabbit alkaline phosphatase and HRP
conjugated secondary antibodies (BioRad and Pierce).
2.2. Grading donor eyes
Eyes obtained from Caucasian donors from the Minnesota Lions
Eye Bank were acquired with consent of the donor or donor family
to be used for medical research in accordance with the principals out-
lined in the Declaration of Helsinki. Criteria established by the MGS
[11] were used to determine the stage of AMD according to established
guidelines. MGS4 is subdivided into individuals with (exudative
AMD) or without (atrophic AMD) neovascularization. All MGS4
donors used in this study had exudative AMD. Eyes were screened
for and excluded if other retinal diseases were observed.
2.3. Preparation of retinal homogenates
Dissection of the sensory retina was performed as reported previ-
ously [13]. The macula was harvested using a 6 mm trephine punch.
The periphery includes retina outside this 6 mm macular region.
2.4. Rat retinal protein stability
Five-month-old Fischer 344 rats were purchased from the Veteri-
nary Medical Unit at the Minneapolis Veterans Aﬀairs Medical Cen-
ter’s aging rodent colony, which is maintained by the University of
Minnesota. An animal protocol was approved by the Institutional Ani-
mal Care and Use Committee of the University of Minnesota. In these
experiments, the post-mortem conditions of human donor eyes were
replicated using rat eyes. In brief, one eye from each rat was immedi-
ately enucleated and served as a control for the paired eyes that were
dissected 2–24 h post-mortem. Bodies were maintained at room tem-
perature for 2.5 h then refrigerated until enucleation at 4.5 h post-mor-
tem. After enucleation, eyes were stored in a moist chamber at 4 Cblished by Elsevier B.V. All rights reserved.
Fig. 1. Post-mortem proteasome activity. One eye from each F344 rat
was immediately enucleated and served as a control for the paired eye;
paired eyes replicated eye bank conditions. Retinal homogenates were
assayed for proteasome activity by measuring the hydrolysis of
ﬂuorogenic peptides LLE-AMC (circles and solid line), VGR-AMC
(triangles and dashed line), and LLVY-AMC (squares and uneven
dashed line). The bracket represents the time range for human donor
eyes in this study. Data are activity relative to the control eye. Values
are the mean ± S.E.M. n = 2–3 rats per time point.
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zen at 80 C and were later processed as outlined above for human
retinas [13].
2.5. Measurement of proteasome activity
The ﬂuorogenic peptides LLE-AMC (200 lM), LLVY-AMC
(75 lM), and VGR-AMC (150 lM) were used as model substrates to
test the caspase-like, chymotrypsin-like, and trypsin-like activities of
the proteasome, respectively [14]. Retinal homogenates (3 lg) were
pre-incubated in the absence or presence of proteasome inhibitors
MG132 (200 lM) or lactacystin (50 lM) in reaction buﬀer prior to
the addition of substrate. Proteasome activity was measured as
described previously [15]. All samples were assayed in triplicate.
2.6. Western immunoblotting of 1D gels
Following 6% or 13% SDS–PAGE, retinal proteins were transferred
to PVDF membranes as described [12]. For each antibody, 35 lg of
protein was resolved, which was within the linear range of response.
PVDF membranes were probed with the monoclonal antibodies
(HSP90 and a7) or polyclonal antibodies that recognize proteasomal
subunits (C2, b5, b5i, b1, and b1i) or regulators (PA28a, PA200,
PA700-S4). The monoclonal antibody, CD45, was used to test for evi-
dence of inﬁltration of immune cells. Jurkat cell lysates were used as a
positive control. Appropriate secondaries were used in conjunction
with BCIP-NBT or chemiluminescence to visualize the immunoreac-
tion. Membranes were imaged with a GS800 Densitometer or Chemi-
Doc (BioRad), followed by quantiﬁcation with Quantity One
(BioRad). All 1D densities were normalized to a standard used on
all blots [13].
2.7. Proteasome content
The immune reactions of the a7 subunit for 20S proteasome puriﬁed
from rat liver [16] and human retinal homogenates were compared to
determine the relative amount of proteasome in retinal homogenates.
2.8. Statistical analysis
Data are reported as mean ± standard error of the mean (S.E.M.).
The S.E.M. for ratios b5i/b5, b1i/b1, and b5i/CD45 were corrected
for the propagation of errors. The relationship between MGS stage
and either activity or immunoblot density were compared using linear
regression. Outliers were removed if they were >2.5 standard devia-
tions (S.D.) from the mean. All statistical tests were two-sided with
a = 0.05.3. Results
3.1. Experimental design
The MGS [11] was used to classify donor eyes into four pro-
gressive stages (MGS1–4) of AMD. MGS1 serves as the con-
trol group. MGS2 represents early stage AMD, MGS3 is an
intermediate stage, and MGS4 is considered end stage (late)
AMD. The macula and periphery of the neurosensory retina
from human donor eyes were analyzed separately to determine
if the preferential deterioration of the macula observed clini-
cally is manifested at the molecular level.
3.2. Proteasome stability post-mortem
Demographic and clinical information for donor eyes
obtained from the Minnesota Lions Eye Bank is similar to
those published previously [12,13]. Post-mortem conditions
prior to tissue preparation did not diﬀer between the four
MGS groups, including the time from death to tissue freezing
(average ± S.D.=16.6 ± 4.0). Due to the broad range in tissue
freezing times among donors in our study (range = 7.5–
22.0 h), we tested proteasome activity and content in rats that
replicated the average handling conditions for donor eyes (see
Section 2). Using ﬂuorogenic peptides, we found proteasomechymotrypsin-like, trypsin-like, and caspase-like activity
decreased with time to freezing up to 8 h (Fig. 1). Activity re-
mained stable from 8 to 24 h post-mortem, which corresponds
to the time range for donor eyes. Furthermore, the content of
a7 remained constant during this time, implying there was no
appreciable degradation of 20S (data not shown). Based on
these results, diﬀerences in freezing times for donor eyes should
not inﬂuence our experimental results.
3.3. Increased retinal proteasome activity with AMD
Using ﬂuorogenic peptide substrates, activity of the three
catalytic sites of the proteasome was measured in human reti-
nal homogenates from both the macula and periphery at four
stages of AMD. The chymotrypsin-like activity was signiﬁ-
cantly increased with disease progression in both the macula
(P = 0.038) and the periphery (P = 0.031), while the trypsin-
like and caspase-like activities remained unchanged (Fig. 2).
Since it is primarily the chymotryptic-like activity that deter-
mines the rate of protein breakdown [17], the increased activity
likely results in an increased rate of protein degradation as
AMD progresses.
3.4. Proteasome content remains constant
One possible explanation for the increased activity is that
proteasome content is upregulated. Content was estimated
from the levels of the a7 subunit, which is a constitutive com-
ponent of the 20S catalytic core and therefore a good estimate
of the total content [15]. Densitometric analysis following
immunoblotting showed no change in total content of protea-
some with progression of the disease (Fig. 3A) in either the
macula (P = 0.65) or periphery (P = 0.33). These results were
conﬁrmed using another a-subunit, a6 (data not shown). Com-
paring the immune reactions of the a7 subunit in a standard of
20S proteasome puriﬁed from liver with the retinal homoge-
nates, we estimated the content of proteasome to be
Fig. 3. Content of 20S proteasomal subunits in AMD retinal tissue.
Relative content of proteasome subunit a7 and representative immu-
noblot (A) in the macula (M) and periphery (P). Exchange of
constitutive subunits b1 and b5 for inducible subunits b1i and b5i in
the macula (B) and periphery (C) at MGS1 (grey), MGS2 (diagonal),
MGS3 (vertical), MGS4 (black). Corresponding representative immu-
noblots from donors at MGS1-4 are shown to the left. *P = 0.001,
Pˆ = 0.007, +P = 0.047, P = 0.037, n = 6–10 for each group tested in
both the macula and periphery.
Fig. 2. Proteasome activity in donor retinas with AMD. Hydrolysis of
ﬂuorogenic peptides measuring the caspase-like (LLE), trypsin-like
(VGR), and chymotrypsin-like (LLVY) activities, were determined in
the macula (A) and periphery (B) from donors at MGS1 (grey), MGS2
(diagonal), MGS3 (vertical), MGS4 (black). *P = 0.038, ˆP = 0.031,
n = 6–9 for each group tested in both the macula and periphery.
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uniform content through disease progression suggests that
the increase in activity is due to an increase in proteasome spe-
ciﬁc activity.
3.5. Increased cytokine-induced catalytic subunits with AMD
It has been previously shown that the inducible b-subunits of
the 20S core can alter the proteolytic activity of the protea-
some [18,19]. Therefore, we examined the levels of both the
constitutive b1 and b5 subunits along with their inducible
counterparts, b1i and b5i, to determine whether a change in
subunit composition could explain the increased speciﬁc
activity with disease progression. Because the total level of
proteasome is not altered with disease, we expect that if induc-
ible subunits increased, there would be a corresponding
decrease in constitutive subunits. We found that the exchange
of constitutive b-subunits for their inducible counterparts
occurs between MGS1 and MGS4 (Fig. 3B and C) in both
the macula and periphery. These results are consistent with
higher expression of the immunoproteasome with AMD pro-
gression.
To address the possibility that the observed increase of
inducible subunits is due to inﬁltrating immune cells contain-
ing high levels of immunoproteasome, we assayed the level
of CD45 in retinal tissue. CD45 is expressed in all bone-mar-
row derived immune cells including resident microglia and
inﬁltrating immune cells in the retina. If there was signiﬁcant
inﬁltration of immune cells into the retinal tissue, we should
see a concomitant increase in levels of CD45 and immunopro-
teasome subunits. In samples from the macula and periphery,we observed that although there was no increase in CD45
(Fig. 4A), there was a dramatic increase in content of immuno-
proteasome subunit b5i (Fig. 4B). To account for the level of
CD45 in each donor, we calculated the ratio of b5i and
CD45 immune density (Fig. 4C). These results closely replicate
the graph of b5i content alone. Although we cannot deﬁni-
tively say whether immune cells have entered the neurosensory
retina, given the limitations of the sensitivity of this assay, we
feel conﬁdant that the increased content of immunoprotea-
some subunits at late stage AMD is not simply due to the con-
tribution from inﬁltrating immune cells but rather reﬂects
changes in retinal proteasome composition.3.6. Proteasome regulatory proteins
Additional mechanisms for increased proteasome speciﬁc
activity includes the association of the 20S core with regulatory
complexes such as PA28 and PA700 [20]. Using antibodies that
recognize the a-subunit of PA28 and the S4 subunit of PA700,
we measured the relative concentration of these proteasome
activators (Fig. 5). No change in PA700 S4 was observed in
the macula (P = 0.54) or periphery (P = 0.83). PA28a content
was uniform in the periphery (P = 0.42), but was increased
(P = 0.07) by MGS4 in the macula. Thus, in the macula,
Fig. 4. CD45 and immunoproteasome subunit levels. (A) Relative
content of CD45, present in bone-marrow derived immune cells, was
measured at progressive levels of MGS from the macular (M, white
wavy bars) and peripheral (P, gray bars) regions of the retina. The inset
shows representative immunoblots. (B) Relative content of b5i from
donor tissue used in (A). The inset shows representative immunoblots.
(C) b5i levels normalized to the content of CD45 were calculated as the
ratio of the densities (b5i/CD45) for each donor. n = 2–4 for each
group tested in both the macula and periphery.
Fig. 5. Content of proteasomal regulatory proteins. Relative content
of regulatory complexes PA28, PA700, PA200 and HSP90 were
measured in the macula (A) and periphery (B) from donors at MGS1
(grey), MGS2 (diagonal), MGS3 (vertical), MGS4 (black).
*P = 0.0001, ˆP = 0.071, +P = 0.058, n = 6–10 for each group tested in
both the macula and periphery.
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immunoproteasome subunits [19].
Two additional auxillary proteins, PA200 and HSP90, have
been shown to regulate proteasome activity. PA200 is a prote-
asomal activator whose biological roles are currently poorly
understood [20]. PA200 content was signiﬁcantly decreased
in the macula (P = 0.0001) and demonstrated a strong trend
in the periphery (P = 0.058). HSP90 has been shown to have
the dual function of inhibiting the constitutive proteasome
and activating the immunoproteasome [20]. Although HSP90
was highly variable between donors, no signiﬁcant correlation
with disease stage in either the macula (P = 0.95) or periphery
(P = 0.89) was detected.4. Discussion
Most aging studies focused on the proteasome report an age-
related decline in activity, which has been suggested as an
explanation for accumulation of oxidized proteins in aged
tissue [21]. In the current study, MGS4 donors were statisti-
cally older (P = 0.01) (86 ± 13 yr, mean ± S.D., n = 10) than
donors in MGS1-3 (71 ± 6 yr, mean ± S.D., n = 30). Since
the increase in chymotrypsin-like activity by MGS4 is contrary
to the expected age-related decrease in activity, we concluded
the increased activity reﬂects alterations due to the disease.
Inﬂammation has been proposed to play an important role
in AMD pathology based upon proteomic [22] and immuno-
histochemical [8] evidence that detected complement proteins
in drusen and by the identiﬁcation of a risk-conferring comple-
ment factor H polymorphism [23–26]. The complement system
is a key element of the innate immune response. Local inﬂam-
mation leads to the production of cytokines [27] that can
upregulate both immunoproteasome subunits and the protea-
some activator PA28 [3]. Therefore, the dramatic upregulation
of immunoproteasome subunits b1i and b5i observed in both
the macular and peripheral neurosensory retina, as well as
increased PA28 in the macular region, supports the presence
of local inﬂammation at end stage of AMD. However, the
uncoordinated regulation of PA28 and inducible subunit
expression suggests other mechanisms may be involved.
The expression of inducible subunits in disease-free MGS1
immune-priviledged retina implies that the immunoprotea-
some may participate in non-immune functions. This idea is
further supported by the presence of non-cytokine response
C.M. Ethen et al. / FEBS Letters 581 (2007) 885–890 889elements in the promoter region in the mouse b5i gene [28]. An
emerging hypothesis is that immunoproteasome plays a pro-
tective role during oxidative stress [29,30]. Data in support
of this hypothesis includes upregulation of inducible subunits
by nitric oxide [31] and an increase in oxidized proteins with
a b1i knockout model [30]. A major ﬁnding with AMD is
the accumulation of oxidized proteins in retinal tissue [7].
Therefore, increased immunoproteasome may reﬂect a com-
pensatory, albeit insuﬃcient, response to the oxidative stress
since oxidized proteins accumulate with the disease.
The prominent increase of immunoproteasome at end stage
does not explain the gradual disease-related increase in chymo-
tryptic activity. This prompted further investigation of cellular
regulators of proteasome function. Levels of proteasome acti-
vators measured in this study revealed increased PA28 and
decreased PA200, although the physiological signiﬁcance of
the latter remains uncertain [20]. Several inhibitors that we
did not investigate may also play a role in regulating protea-
some activity. Some of the recently discovered inhibitors
PI31, Tat, HBx, and PR39 compete with PA28 for the same
binding sites on a-subunits of the 20S core [20]. PR39 is re-
ported to stimulate angiogenesis and suppress inﬂammation
by inhibiting proteasome mediated degradation of HIF1a
[20,27] and will be of interest for future studies.
Regulation of the proteasome is of profound importance for
cellular function. We interpret the presence of immunoprotea-
some at later stages of AMD as an indicator of local inﬂamma-
tion or increased oxidative stress in the neurosensory retina.
Further studies are required to understand the underlying
mechanisms behind immunoproteasome upregulation and the
functional consequences of proteasome transformation in
AMD pathology.
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